A general perspective for the conduct of radiolabelled distribution, metabolism, and excretion studies for antibody-drug conjugates

• Published in: Xenobiotica 2024-09, Vol.54 (8), p.521-532
• Main Authors: Rudolph, Bettina, Davis, John A, Hainzl, Dominik, Walles, Markus
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - pharmacokinetics; Humans; Immunoconjugates - pharmacokinetics; Tissue Distribution
• ISSN: 0049-8254; 1366-5928; 1366-5928
• DOI: 10.1080/00498254.2024.2336576

Antibody-drug conjugates (ADCs) are a class of biopharmaceuticals that combine the specificity of monoclonal antibodies (mAbs) with the cytotoxicity of small molecule drugs. 15 ADCs have been approved by regulatory authorities up to now, mainly for indications in oncology, however, this review paper will only focus on the 13 ADCs that have been approved by either the FDA or EMA.ADME (Absorption, Distribution, Metabolism, and Excretion) studies are essential for the development of small molecule drugs to evaluate their disposition properties. These studies help to select drug candidates, determine the optimal dosing regimen and help to identify potential safety concerns for the drug of interest in human. Tissue distribution studies are also important as they facilitate the understanding of the efficacy and safety for parent drug and its metabolites in preclinical and clinical studies.For biologics, ADME studies are usually not required. In this paper, we review the existing approval packages and literature for approved ADCs to determine the extent of ADME studies performed as part of ADC registration packages.We conclude that ADME studies are recommended for the development of ADCs if new linkers and payloads are used that have never been used in humans before as these studies provide valuable information on the pharmacokinetic properties, optimal dosing regimen, and potential safety concerns. However, for the development of ADCs with established linker payload combinations, radiolabelled ADME studies may not be necessary if the distribution, metabolism and excretion properties have been described before. Clinical radiolabelled ADME studies are not recommended where patients are treated for life threating diseases like for indications in oncology.